Switch theme
Sign up to access all valuation multiples
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
1983
186
LTM Revenue $6.1M
LTM EBITDA -$200M
$459M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Celldex Therapeutics has a last 12-month revenue of $6.1M and a last 12-month EBITDA of -$200M.
In the most recent fiscal year, Celldex Therapeutics achieved revenue of $7.0M and an EBITDA of -$192M.
Celldex Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Celldex Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.9M | $7.0M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$139M | -$192M | XXX | XXX | XXX |
| EBITDA Margin | -2020% | -2734% | XXX | XXX | XXX |
| Net Profit | -$112M | -$141M | XXX | XXX | XXX |
| Net Margin | -1632% | -2015% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Celldex Therapeutics's stock price is $18.
Celldex Therapeutics has current market cap of $1.2B, and EV of $459M.
See Celldex Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $459M | $1.2B | XXX | XXX | XXX | XXX | $-2.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Celldex Therapeutics has market cap of $1.2B and EV of $459M.
Celldex Therapeutics's trades at 75.9x LTM EV/Revenue multiple, and -2.3x LTM EBITDA.
Analysts estimate Celldex Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Celldex Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $459M | XXX | XXX | XXX |
| EV/Revenue | 65.5x | XXX | XXX | XXX |
| EV/EBITDA | -2.4x | XXX | XXX | XXX |
| P/E | -7.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCelldex Therapeutics's NTM/LTM revenue growth is -43%
Celldex Therapeutics's revenue per employee for the last fiscal year averaged $38K, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Celldex Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Celldex Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Celldex Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -2734% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 38% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -2776% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $38K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 549% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2330% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2879% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celldex Therapeutics acquired XXX companies to date.
Last acquisition by Celldex Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Celldex Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Celldex Therapeutics founded? | Celldex Therapeutics was founded in 1983. |
| Where is Celldex Therapeutics headquartered? | Celldex Therapeutics is headquartered in United States of America. |
| How many employees does Celldex Therapeutics have? | As of today, Celldex Therapeutics has 186 employees. |
| Who is the CEO of Celldex Therapeutics? | Celldex Therapeutics's CEO is Mr. Anthony S. Marucci. |
| Is Celldex Therapeutics publicy listed? | Yes, Celldex Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Celldex Therapeutics? | Celldex Therapeutics trades under CLDX ticker. |
| When did Celldex Therapeutics go public? | Celldex Therapeutics went public in 1990. |
| Who are competitors of Celldex Therapeutics? | Similar companies to Celldex Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Celldex Therapeutics? | Celldex Therapeutics's current market cap is $1.2B |
| What is the current revenue of Celldex Therapeutics? | Celldex Therapeutics's last 12-month revenue is $6.1M. |
| What is the current EBITDA of Celldex Therapeutics? | Celldex Therapeutics's last 12-month EBITDA is -$200M. |
| What is the current EV/Revenue multiple of Celldex Therapeutics? | Current revenue multiple of Celldex Therapeutics is 75.9x. |
| What is the current EV/EBITDA multiple of Celldex Therapeutics? | Current EBITDA multiple of Celldex Therapeutics is -2.3x. |
| What is the current revenue growth of Celldex Therapeutics? | Celldex Therapeutics revenue growth between 2023 and 2024 was 2%. |
| Is Celldex Therapeutics profitable? | Yes, Celldex Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
